SELLAS Q3 net loss $9.3M; GPS Phase 3 enrollment complete, SLS009 shows CR in AML

SELLAS Life Sciences Group, Inc.

2023-Q3 EPS reported -$1.09

Net loss $9.3M ($0.33/share) vs $7.0M in Q3 2022; cash $4.0M as of Sep 30, 2023; subsequent $4.0M offering.
Phase 3 REGAL trial of GPS in AML expected to complete enrollment (ex-China) in November 2023; interim data late 2023/early 2024.
SLS009 Phase 2a in AML: first patient achieved complete response, six of seven patients alive; anti-leukemic effects in all.
FDA granted Orphan Drug Designation for SLS009 in AML and Fast Track for r/r PTCL.
Anticipating $13.0M milestone from 3D Medicines upon China enrollment in REGAL in Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2023 and providing a corporate update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001390478-23-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.